Cover Image
市場調查報告書

S.L.A. Pharma AG: 產品平台分析

S.L.A. Pharma AG - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 200994
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
S.L.A. Pharma AG: 產品平台分析 S.L.A. Pharma AG - Product Pipeline Review - 2014
出版日期: 2014年09月15日 內容資訊: 英文 31 Pages
簡介

S.L.A. Pharma AG 是針對胃腸障礙及罕見疾病的預防和治療藥開發的製藥公司。該公司產品常應用於肛門裂傷、肛門周圍的克隆氏症、家族性腺瘤息肉症,Opioids(類鴉片物質)誘發性便秘,航班失禁等治療上。

本報告提供S.L.A. Pharma AG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

S.L.A. Pharma AG的基本資料

  • S.L.A. Pharma AG概要
  • 主要資訊
  • 企業資料

S.L.A. Pharma AG:R&D概要

  • 主要的治療範圍

S.L.A. Pharma AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

S.L.A. Pharma AG:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式

S.L.A. Pharma AG:藥物簡介

  • diltiazem hydrochloride
  • icosapent ethyl
  • metronidazole
  • naloxone hydrochloride SR
  • phenylephrine

S.L.A. Pharma AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

S.L.A. Pharma AG:最近的開發平台趨勢

S.L.A. Pharma AG:暫停中的計劃

S.L.A. Pharma AG:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • diltiazem hydrochloride

S.L.A. Pharma AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06373CDB

Summary

Global Markets Direct's, 'S.L.A. Pharma AG - Product Pipeline Review - 2014', provides an overview of the S.L.A. Pharma AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of S.L.A. Pharma AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of S.L.A. Pharma AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of S.L.A. Pharma AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the S.L.A. Pharma AG's pipeline products

Reasons to buy

  • Evaluate S.L.A. Pharma AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of S.L.A. Pharma AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the S.L.A. Pharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of S.L.A. Pharma AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of S.L.A. Pharma AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of S.L.A. Pharma AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • S.L.A. Pharma AG Snapshot
    • S.L.A. Pharma AG Overview
    • Key Information
    • Key Facts
  • S.L.A. Pharma AG - Research and Development Overview
    • Key Therapeutic Areas
  • S.L.A. Pharma AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • S.L.A. Pharma AG - Pipeline Products Glance
    • S.L.A. Pharma AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • S.L.A. Pharma AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • S.L.A. Pharma AG - Drug Profiles
    • diltiazem hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • icosapent ethyl
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • metronidazole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naloxone hydrochloride SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • phenylephrine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • S.L.A. Pharma AG - Pipeline Analysis
    • S.L.A. Pharma AG - Pipeline Products by Target
    • S.L.A. Pharma AG - Pipeline Products by Route of Administration
    • S.L.A. Pharma AG - Pipeline Products by Molecule Type
    • S.L.A. Pharma AG - Pipeline Products by Mechanism of Action
  • S.L.A. Pharma AG - Recent Pipeline Updates
  • S.L.A. Pharma AG - Dormant Projects
  • S.L.A. Pharma AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • diltiazem hydrochloride
  • S.L.A. Pharma AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • S.L.A. Pharma AG, Key Information
  • S.L.A. Pharma AG, Key Facts
  • S.L.A. Pharma AG - Pipeline by Indication, 2014
  • S.L.A. Pharma AG - Pipeline by Stage of Development, 2014
  • S.L.A. Pharma AG - Monotherapy Products in Pipeline, 2014
  • S.L.A. Pharma AG - Phase III, 2014
  • S.L.A. Pharma AG - Phase II, 2014
  • S.L.A. Pharma AG - Pipeline by Target, 2014
  • S.L.A. Pharma AG - Pipeline by Route of Administration, 2014
  • S.L.A. Pharma AG - Pipeline by Molecule Type, 2014
  • S.L.A. Pharma AG - Pipeline Products by Mechanism of Action, 2014
  • S.L.A. Pharma AG - Recent Pipeline Updates, 2014
  • S.L.A. Pharma AG - Dormant Developmental Projects,2014
  • S.L.A. Pharma AG - Discontinued Pipeline Products, 2014
  • S.L.A. Pharma AG, Subsidiaries

List of Figures

  • S.L.A. Pharma AG - Pipeline by Top 10 Indication, 2014
  • S.L.A. Pharma AG - Pipeline by Stage of Development, 2014
  • S.L.A. Pharma AG - Monotherapy Products in Pipeline, 2014
  • S.L.A. Pharma AG - Pipeline by Top 10 Target, 2014
  • S.L.A. Pharma AG - Pipeline by Top 10 Route of Administration, 2014
  • S.L.A. Pharma AG - Pipeline by Top 10 Molecule Type, 2014
  • S.L.A. Pharma AG - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top